Study Evaluating Safety and Efficacy of JCAR017 in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL)
Leukemia, Lymphocytic, Chronic, B-Cell · Lymphoma, Small Lymphocytic
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
- +2.6
2 insiders sold shares within a month
Since Sep 9, 2026 · was worth 5, fading over time
Score over time
- Stage
- Phase 1/2
- Patients
- 320 (planned)
- Started
- Nov 27, 2017
- Main results expected
- Nov 26, 2027
- Fully finished
- Nov 26, 2027
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Phase 1 JCAR017 monotherapy arm: adverse events
Measured over: Up to 48 months post treatment
Phase 1 JCAR017 monotherapy arm: laboratory abnormalities
Measured over: Up to 48 months post treatment
Phase 1 JCAR017 and ibrutinib combination dose escalation therapy arm: adverse events
Measured over: Up to 48 months post treatment
Phase 1 JCAR017 and ibrutinib combination dose escalation therapy arm: laboratory abnormalities
Measured over: Up to 48 months post treatment
Phase 1 JCAR017 and ibrutinib combination dose expansion therapy arm
Measured over: Through post treatment up to Month 48
Phase 1 JCAR017 and venetoclax combination dose escalation therapy arm: adverse events
Measured over: Up to 48 months post treatment
Phase 1 JCAR017 and venetoclax combination dose escalation therapy arm: laboratory abnormalities
Measured over: Up to 48 months post treatment
Phase 1 JCAR017 and venetoclax combination dose expansion therapy arm
Measured over: Through post treatment up to Month 48
Phase 2 JCAR017 monotherapy expansion arm
Measured over: Through post treatment up to Month 48
Phase 2 JCAR017 Double exposed monotherapy expansion arm: overall response rate (ORR)
Measured over: Up to approximately 24 months
Changes Tremor has spotted
Show details (technical version)
Score inputs
- insider_selling_cluster: base 5, now 2.6, since 2026-09-09, fades (half-life)
Raw record changes
- none yet
Trial ID NCT03331198 · record last updated 2026-07-06 · checked 2026-11-09 15:47 UTC